HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood-brain barrier.

Abstract
The inhibition potencies of aripiprazole and its active metabolite, dehydroaripiprazole, on the activities of human multidrug resistance protein 1 (MDR1/ABCB1; P-glycoprotein), breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated protein 4 (MRP4/ABCC4), that are drug efflux transporters expressed both in the intestine and at the blood-brain barrier (BBB), were investigated. Aripiprazole and dehydroapripiprazole showed relatively strong inhibitory effects on human MDR1 with IC(50) values of 1.2 and 1.3 µm in human MDR1-transfected Mardin-Darby canine kidney (MDCKII-MDR1) cells, respectively. The inhibition potencies of other atypical antipsychotics (risperidone, paliperidone, olanzapine and ziprasidone) for human MDR1 were also evaluated using the same in vitro experimental system and IC(50) values were more than 10-fold higher than those of the two compounds. Aripiprazole and dehydroaripiprazole also had inhibition potencies against human BCRP with IC(50) values of 3.5 and 0.52 µm, respectively. The ratios of steady-state unbound concentrations of aripiprazole and dehydroaripiprazole to their IC(50) values against human MDR1 and BCRP activities were less than 0.1, whereas the theoretically maximum gastrointestinal concentration of aripiprazole ([I](2) ) to its IC(50) values was much higher than the cut-off value of 10, proposed by the International Transporter Consortium (ITC) and the Food and Drug Administration (FDA). In contrast, aripiprazole and dehydroaripiprazole showed almost no inhibitory effect against the activity of human MRP4. These findings indicate that aripiprazole is unlikely to cause drug-drug interactions (DDIs) at the BBB when co-administered with substrate drugs of these drug transporters investigated. However, interactions at the intestinal absorption process may be of concern.
AuthorsYasuhisa Nagasaka, Kazuo Oda, Takafumi Iwatsubo, Akio Kawamura, Takashi Usui
JournalBiopharmaceutics & drug disposition (Biopharm Drug Dispos) Vol. 33 Issue 6 Pg. 304-15 (Sep 2012) ISSN: 1099-081X [Electronic] England
PMID22847220 (Publication Type: Journal Article)
CopyrightCopyright © 2012 John Wiley & Sons, Ltd.
Chemical References
  • ABCB1 protein, human
  • ABCC4 protein, human
  • ABCG2 protein, human
  • ATP Binding Cassette Transporter, Subfamily B
  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • ATP Binding Cassette Transporter, Subfamily G, Member 2
  • ATP-Binding Cassette Transporters
  • Antipsychotic Agents
  • Multidrug Resistance-Associated Proteins
  • Neoplasm Proteins
  • Piperazines
  • Quinolones
  • Digoxin
  • Aripiprazole
Topics
  • ATP Binding Cassette Transporter, Subfamily B
  • ATP Binding Cassette Transporter, Subfamily B, Member 1 (antagonists & inhibitors, genetics, metabolism)
  • ATP Binding Cassette Transporter, Subfamily G, Member 2
  • ATP-Binding Cassette Transporters (antagonists & inhibitors, genetics, metabolism)
  • Animals
  • Antipsychotic Agents (metabolism, pharmacology)
  • Aripiprazole
  • Biotransformation
  • Blood-Brain Barrier (drug effects, metabolism)
  • Digoxin (metabolism)
  • Dogs
  • Dose-Response Relationship, Drug
  • Drug Interactions
  • Humans
  • Intestinal Mucosa (metabolism)
  • Intestines (drug effects)
  • Madin Darby Canine Kidney Cells
  • Models, Biological
  • Multidrug Resistance-Associated Proteins (antagonists & inhibitors, genetics, metabolism)
  • Neoplasm Proteins (antagonists & inhibitors, genetics, metabolism)
  • Permeability
  • Piperazines (metabolism, pharmacology)
  • Quinolones (metabolism, pharmacology)
  • Transfection

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: